scholarly journals Structure modeling and spatial epitope analysis for HA protein of the novel H1N1 influenza virus

2009 ◽  
Vol 54 (13) ◽  
pp. 2171-2173 ◽  
Author(s):  
Di Wu ◽  
TianLei Xu ◽  
Jing Sun ◽  
JianXin Dai ◽  
GuoHui Ding ◽  
...  
Keyword(s):  
Influenza Virus ◽  
H1n1 Influenza ◽  
Structure Modeling ◽  
The Novel ◽  
H1n1 Influenza Virus ◽  
Epitope Analysis ◽  
Novel H1n1 Influenza ◽  
Ha Protein

scholarly journals Sequential Seasonal H1N1 Influenza Virus Infections Protect Ferrets against Novel 2009 H1N1 Influenza Virus

2012 ◽  
Vol 87 (3) ◽  
pp. 1400-1410 ◽  
Author(s):  
Donald M. Carter ◽  
Chalise E. Bloom ◽  
Eduardo J. M. Nascimento ◽  
Ernesto T. A. Marques ◽  
Jodi K. Craigo ◽  
...  
Keyword(s):  
Influenza Virus ◽  
H1n1 Influenza ◽  
Cross Reactivity ◽  
Influenza Viruses ◽  
The Novel ◽  
Virus Infections ◽  
H1n1 Influenza Virus ◽  
Virus Shedding ◽  
2009 H1n1 ◽  
Novel H1n1 Influenza

ABSTRACTIndividuals <60 years of age had the lowest incidence of infection, with ∼25% of these people having preexisting, cross-reactive antibodies to novel 2009 H1N1 influenza. Many people >60 years old also had preexisting antibodies to novel H1N1. These observations are puzzling because the seasonal H1N1 viruses circulating during the last 60 years were not antigenically similar to novel H1N1. We therefore hypothesized that a sequence of exposures to antigenically different seasonal H1N1 viruses can elicit an antibody response that protects against novel 2009 H1N1. Ferrets were preinfected with seasonal H1N1 viruses and assessed for cross-reactive antibodies to novel H1N1. Serum from infected ferrets was assayed for cross-reactivity to both seasonal and novel 2009 H1N1 strains. These results were compared to those of ferrets that were sequentially infected with H1N1 viruses isolated prior to 1957 or more-recently isolated viruses. Following seroconversion, ferrets were challenged with novel H1N1 influenza virus and assessed for viral titers in the nasal wash, morbidity, and mortality. There was no hemagglutination inhibition (HAI) cross-reactivity in ferrets infected with any single seasonal H1N1 influenza viruses, with limited protection to challenge. However, sequential H1N1 influenza infections reduced the incidence of disease and elicited cross-reactive antibodies to novel H1N1 isolates. The amount and duration of virus shedding and the frequency of transmission following novel H1N1 challenge were reduced. Exposure to multiple seasonal H1N1 influenza viruses, and not to any single H1N1 influenza virus, elicits a breadth of antibodies that neutralize novel H1N1 even though the host was never exposed to the novel H1N1 influenza viruses.

Electrocardiographic Abnormalities in Patients With Novel H1N1 Influenza Virus Infection

2010 ◽  
Vol 106 (10) ◽  
pp. 1517-1519 ◽  
Author(s):  
Nikolaos Akritidis ◽  
Maria Mastora ◽  
Gerasimos Baxevanos ◽  
Georgios Dimos ◽  
Georgios Pappas
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Influenza Virus Infection ◽  
H1n1 Influenza ◽  
H1n1 Influenza Virus ◽  
Novel H1n1 Influenza ◽  
Electrocardiographic Abnormalities

The Novel 2009 H1N1 Influenza Virus Pandemic: Unique Considerations for Programs in Cardiothoracic Transplantation

2009 ◽  
Vol 28 (12) ◽  
pp. 1341-1347 ◽  
Author(s):  
Lara A. Danziger-Isakov ◽  
Shahid Husain ◽  
Martha L. Mooney ◽  
Margaret M. Hannan
Keyword(s):  
Influenza Virus ◽  
H1n1 Influenza ◽  
The Novel ◽  
H1n1 Influenza Virus ◽  
2009 H1n1

Utility of Influenza Vaccination for Oncology Patients

2010 ◽  
Vol 28 (14) ◽  
pp. 2481-2490 ◽  
Author(s):  
Daniel A. Pollyea ◽  
Janice M.Y. Brown ◽  
Sandra J. Horning
Keyword(s):  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Hematologic Malignancies ◽  
H1n1 Influenza ◽  
The Novel ◽  
H1n1 Influenza Virus ◽  
Immunological Responses ◽  
Patients With Cancer ◽  
H1n1 Strain ◽  
Novel H1n1 Influenza

Every fall and winter, patients with cancer and their families ask oncologists whether they should be vaccinated for influenza. This season, with escalating concerns regarding the novel H1N1 influenza virus and its recently approved vaccine, this question has become more frequent and increasingly urgent. The purpose of this article is to review evidence related to the ability of patients with cancer to mount protective immunological responses to influenza vaccination. The literature on immunogenicity in pediatric and adult patients, those with solid tumors and hematologic malignancies, untreated and actively treated patients, and patients receiving biologic agents is summarized and reviewed. In addition, we report on potential strategies to improve the efficacy of influenza vaccination in patients with cancer, such as the timing of vaccination, use of more than a one-shot series, increasing the antigen dose, and the use of adjuvant therapies. We conclude that there is evidence that patients with cancer receiving chemotherapy are able to respond to influenza vaccination, and because this intervention is safe, inexpensive, and widely available, vaccination for seasonal influenza and the novel H1N1 strain is indicated.

A Rapid Medical Screening Process Improves Emergency Department Patient Flow During Surge Associated With Novel H1N1 Influenza Virus

2011 ◽  
Vol 57 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Daniel B. Fagbuyi ◽  
Kathleen M. Brown ◽  
David J. Mathison ◽  
Jennifer Kingsnorth ◽  
Sephora Morrison ◽  
...  
Keyword(s):  
Emergency Department ◽  
Influenza Virus ◽  
Patient Flow ◽  
Emergency Department Patient ◽  
H1n1 Influenza ◽  
H1n1 Influenza Virus ◽  
Medical Screening ◽  
Screening Process ◽  
Novel H1n1 Influenza

Controlling the novel A (H1N1) influenza virus: don't touch your face!

2009 ◽  
Vol 73 (3) ◽  
pp. 280-281 ◽  
Author(s):  
A.E. Macias ◽  
A. de la Torre ◽  
S. Moreno-Espinosa ◽  
P.E. Leal ◽  
M.T. Bourlon ◽  
...  
Keyword(s):  
Influenza Virus ◽  
H1n1 Influenza ◽  
The Novel ◽  
H1n1 Influenza Virus

scholarly journals Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF®01 or CDA/αGalCerMPEG

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 751
Author(s):  
Sergi López-Serrano ◽  
Lorena Cordoba ◽  
Mónica Pérez-Maillo ◽  
Patricia Pleguezuelos ◽  
Edmond J. Remarque ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Immune Responses ◽  
Post Infection ◽  
Influenza Virus Infection ◽  
H1n1 Influenza ◽  
The Novel ◽  
H1n1 Influenza Virus ◽  
Viral Loads ◽  
Viral Shedding ◽  
Trivalent Influenza Vaccine

This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF®01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF®01 or NG34 + CDA/αGCM. As controls, groups of animals (n = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund’s adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 106 TCID50/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF®01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF®01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF®01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF®01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.

scholarly journals Ruling Out Novel H1N1 Influenza Virus Infection with Direct Fluorescent Antigen Testing

2009 ◽  
Vol 49 (6) ◽  
pp. e66-e68 ◽  
Author(s):  
Nira R. Pollock ◽  
Scott Duong ◽  
Annie Cheng ◽  
Linda L. Han ◽  
Sandra Smole ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Influenza Virus Infection ◽  
H1n1 Influenza ◽  
H1n1 Influenza Virus ◽  
Novel H1n1 Influenza ◽  
Antigen Testing
Sign in / Sign up

Export Citation Format

Share Document